Acquisition of Biostrand - Summary of Changes in Value of Subsequent Payments (Detail) - BioStrand B.V. [Member] - CAD ($) $ in Thousands |
12 Months Ended | |
|---|---|---|
Apr. 30, 2025 |
Apr. 30, 2024 |
|
| Disclosure of detailed information about business combination [line items] | ||
| Beginning balance | $ 285 | $ 717 |
| Foreign exchange | 19 | (11) |
| Accretion | 10 | 19 |
| Working capital adjustment | (294) | |
| Deferred acquisition payment | (146) | |
| Ending balance | 314 | $ 285 |
| Less: Current portion | $ (314) | |
| X | ||||||||||
- Definition Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table. No definition available.
|
| X | ||||||||||
- Definition The amount of exchange differences recognised in profit or loss that arise from foreign currency transactions, excluding those arising on financial instruments measured at fair value through profit or loss in accordance with IFRS 9. [Refer: At fair value [member]; Classes of financial instruments [domain]] Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The increase (decrease) in working capital. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Current deferred cash payments. No definition available.
|
| X | ||||||||||
- Definition Deferred acquisition payment. No definition available.
|
| X | ||||||||||
- Definition Deferred acquisition payments. No definition available.
|
| X | ||||||||||
- Definition Deferred payments accretion expense. No definition available.
|
| X | ||||||||||
- Details
|